A Study Comparing CMF (Cyclophosphamide, Methotrexate, 5-fluorouracil) and MMM (Mitozantrone, Methotrexate, Mitomycin-C) Chemotherapy in Patients with Metastatic Breast Cancer

Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Histologically proven breast cancer, metastatic or incurable locally recurrent disease
•2. No other malignancy except adequately treated in situ carcinoma of cervix or non melanomatous skin cancer
•3. Previous adjuvant chemotherapy or neo-adjuvant chemotherapy is acceptable, unless the disease free interval is <2 years following adjuvant CMF chemotherapy
•4. Previous chemotherapy for metastatic disease is acceptable
•5. Patients must be willing to complete quality of life questionnaire and be interviewed by a senior nurse
•6. Normal liver function
•7. Patients must be considered fit enough to receive either standard CMF or MMM chemotherapy

•1. Patients are not eligible if they are eligible for a first line phase II study. Patients may become eligible at the time of progression
•2. Patient are not eligible if they present with immediately life threatening disease for whom the physician considers an anthracycline based combination preferable

发起方

Cancer Research UK (CRUK) (UK)